NAGE Valuation

Niagen Bioscience Inc

Add to Watchlist

Advanced Chart

6.925

-0.065(-0.930%)1D

NAGE Relative Valuation

NAGE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NAGE is overvalued; if below, it's undervalued.

Historical Valuation

Niagen Bioscience Inc (NAGE) is now in the Undervalued zone, suggesting that its current forward PE ratio of 32.47 is considered Undervalued compared with the five-year average of 66.56. The fair price of Niagen Bioscience Inc (NAGE) is between 8.47 to 16.18 according to relative valuation methord. Compared to the current price of 6.92 USD , Niagen Bioscience Inc is Undervalued By 18.24%.

Relative Value

Fair Zone

8.47-16.18

Current Price：6.92

18.24%

Undervalued

32.47

Trailing

Forward

20.61

EV/EBITDA

Niagen Bioscience Inc. (NAGE) has a current EV/EBITDA of 20.61. The 5-year average EV/EBITDA is 43.89. The thresholds are as follows: Strongly Undervalued below 21.09, Undervalued between 21.09 and 32.49, Fairly Valued between 55.29 and 32.49, Overvalued between 55.29 and 66.69, and Strongly Overvalued above 66.69. The current Forward EV/EBITDA of 20.61 falls within the Strongly Undervalued range.

35.06

EV/EBIT

Niagen Bioscience Inc. (NAGE) has a current EV/EBIT of 35.06. The 5-year average EV/EBIT is 64.21. The thresholds are as follows: Strongly Undervalued below 34.45, Undervalued between 34.45 and 49.33, Fairly Valued between 79.09 and 49.33, Overvalued between 79.09 and 93.97, and Strongly Overvalued above 93.97. The current Forward EV/EBIT of 35.06 falls within the Undervalued range.

6.99

Niagen Bioscience Inc. (NAGE) has a current PS of 6.99. The 5-year average PS is 5.80. The thresholds are as follows: Strongly Undervalued below 3.54, Undervalued between 3.54 and 4.67, Fairly Valued between 6.93 and 4.67, Overvalued between 6.93 and 8.06, and Strongly Overvalued above 8.06. The current Forward PS of 6.99 falls within the Overvalued range.

21.65

P/OCF

Niagen Bioscience Inc. (NAGE) has a current P/OCF of 21.65. The 5-year average P/OCF is 41.59. The thresholds are as follows: Strongly Undervalued below 18.94, Undervalued between 18.94 and 30.26, Fairly Valued between 52.92 and 30.26, Overvalued between 52.92 and 64.25, and Strongly Overvalued above 64.25. The current Forward P/OCF of 21.65 falls within the Undervalued range.

22.79

P/FCF

Niagen Bioscience Inc. (NAGE) has a current P/FCF of 22.79. The 5-year average P/FCF is 61.52. The thresholds are as follows: Strongly Undervalued below -4.01, Undervalued between -4.01 and 28.75, Fairly Valued between 94.28 and 28.75, Overvalued between 94.28 and 127.05, and Strongly Overvalued above 127.05. The current Forward P/FCF of 22.79 falls within the Undervalued range.

Niagen Bioscience Inc (NAGE) has a current Price-to-Book (P/B) ratio of 7.90. Compared to its 3-year average P/B ratio of 12.23 , the current P/B ratio is approximately -35.37% higher. Relative to its 5-year average P/B ratio of 12.23, the current P/B ratio is about -35.37% higher. Niagen Bioscience Inc (NAGE) has a Forward Free Cash Flow (FCF) yield of approximately 0.04%. Compared to its 3-year average FCF yield of 2.68%, the current FCF yield is approximately -98.57% lower. Relative to its 5-year average FCF yield of 2.68% , the current FCF yield is about -98.57% lower.

7.90

P/B

Median3y

12.23

Median5y

12.23

0.04

FCF Yield

Median3y

2.68

Median5y

2.68

Competitors Valuation Multiple

The average P/S ratio for NAGE's competitors is 14.77, providing a benchmark for relative valuation. Niagen Bioscience Inc Corp (NAGE) exhibits a P/S ratio of 6.99, which is -52.67% above the industry average. Given its robust revenue growth of 32.86%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

NAGE.O

Niagen Bioscience Inc

ArriVent BioPharma Inc

19.68

812.42M

USNA.N

USANA Health Sciences Inc

Nature's Sunshine Products Inc

Performance Decomposition

Market capitalization of NAGE decreased by 9.46% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 7.34 to 13.47.

The secondary factor is the Revenue Growth, contributed 32.86%to the performance.

Overall, the performance of NAGE in the past 1 year is driven by Margin Expansion. Which is more sustainable.

32.86%

25.58M → 33.99M

Revenue Growth

83.51%

7.34 → 13.47

Margin Expansion

-125.83%

-115.21 → 29.76

P/E Change

-9.46%